



Applicant's Docket No. BMID9814US

DT04 Rec'd PCT/PTO 03 NOV 2003

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Endl, Josef; Wild, Thomas; Berlo, Suzanne Elisabeth; Litty, Verena

Serial No.: 09/786,040

Filed: July 17, 2001

For: HUMAN MONOCLONAL ANTIBODIES TO THE ISLET CELL ANTIGEN IA-2

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

REQUEST FOR CORRECTED FILING RECEIPT

1. Attached is a copy of the official Filing Receipt received from the USPTO in the above application for which issuance of a corrected Filing Receipt is respectfully requested.
2. There are errors with respect to the following, which are incorrectly entered.

Error in

1. Title

Correct data

1. Human Monoclonal Antibodies to the Islet Cell Antigen IA-2


3. The corrections are not due to any error by applicant and no fee is due.

Marilyn L. Amick, Reg. No. 30,444
Roche Diagnostics Corporation
P.O. Box 50457
9115 Hague Road, Bldg D
Indianapolis, IN 46250
Tel. No.: (317) 521-7561
Fax No.: (317) 521-2883

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on this date, October 29, 2003, via First Class Mail.

Marsha Breen



UNITED STATES PATENT AND TRADEMARK OFFICE

BMID 9814 US
(CMA)COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/786,040	07/17/2001	1645	1310	BMID9814US		12	7

CONFIRMATION NO. 8496

FILING RECEIPT



OC000000007221685

Marilyn L Amick
Roche Diagnostics Corporation
9115 Hague Road Building D
P O Box 50457
Indianapolis, IN 46250-0457

Date Mailed: 12/26/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

- ✓ Josef Endl, Weilheim, GERMANY;
- ✓ Thomas Wild, Penzberg, GERMANY;
- ✓ Suzanne Elisabeth Berlo, Haaren, NETHERLANDS;
- ✓ Verena Litty, Planegg, GERMANY;

3/8/02
RR
FR mailed 12/26/01

Domestic Priority data as claimed by applicant

- ✓ THIS APPLICATION IS A 371 OF PCT/EP99/06321 08/27/1999

Foreign Applications

GERMANY 198 39 736.4 01/09/1998

Projected Publication Date: Not Applicable, filed prior to November 29, 2000


Non-Publication Request: No

Early Publication Request: No

Title

✓ Human monoclonal antibodies ^{to} ~~against~~ the islet cell antigen ^{IA-2} ~~IA-2~~

Preliminary Class



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).